Cogent Biosciences, Inc. COGT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $282.12M+4.6% | $269.78M+5.3% | $256.27M+2.1% | $250.89M+3.3% | $242.98M+4.4% | ||
| $79.92M+25.7% | $63.58M+23.9% | $51.34M+5.3% | $48.77M+7.2% | $45.49M+5.1% | ||
| $362.04M+8.6% | $333.36M+8.4% | $307.6M+2.6% | $299.66M+3.9% | $288.47M+4.5% | ||
| -$362.04M-8.6% | -$333.36M-8.4% | -$307.6M-2.6% | -$299.66M-3.9% | -$288.47M-4.5% | ||
| $4.28M+39.6% | $3.06M— | —— | —— | —— | ||
| —— | —— | $13.23M-15.1% | $15.59M-17.8% | $18.97M-5.5% | ||
| -$354.3M-7.7% | -$328.94M-11.7% | -$294.37M-3.6% | -$284.08M-5.4% | -$269.5M-5.3% | ||
| -$2.17-0.5% | -$2.16-5.4% | -$2.05+1.0% | -$2.07-5.1% | -$1.97-1.5% | ||
| -$359.47M-8.7% | -$330.79M-8.4% | -$305.06M-2.7% | -$297.14M-3.9% | -$285.99M-4.6% | ||
| -$362.04M-8.6% | -$333.36M-8.4% | -$307.6M-2.6% | -$299.66M-3.9% | -$288.47M-4.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Cogent Biosciences, Inc.'s revenue?
- Cogent Biosciences, Inc. (COGT) generated $7.9M in revenue over the trailing twelve months, down 65.0% year over year.
- Is Cogent Biosciences, Inc. profitable?
- Cogent Biosciences, Inc. is not currently profitable: it reported a net loss of $354.3M over the trailing twelve months, a -950.4% net margin.
- What is Cogent Biosciences, Inc.'s earnings per share?
- Cogent Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-2.17.
- Where does Cogent Biosciences, Inc.'s income statement data come from?
- Every line is extracted from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
